Dr. Khaled Diab

Executive Health

at Diab Longevity

About

Dr. Khaled Diab leads Diab Longevity as its sole physician and the architect of its clinical methodology. His focus spans biological age reversal, longevity optimization, stem cell therapy, peptide protocols, hormone calibration, and executive health.

Dr. Diab approaches each patient as a biological asset requiring active management. He targets clinical benchmarks drawn from elite athlete and high-performance executive data, not standard population ranges. His stem cell protocols operate under IRB-2024-0847 and meet GMP compliance standards. He is passionate about eliminating silent risk in high-performing adults before it compounds into measurable decline. Through the DiabOS platform, Dr. Diab functions as a direct medical resource for clients, available via secure messaging for real-time guidance on labs, protocols, and emerging findings.

Education & Training

Additional Training

IRB-2024-0847 compliant stem cell protocols; GMP compliance standards

Conditions Treated

hormonal imbalancetestosterone deficiencymetabolic dysfunctionchronic inflammationjoint deteriorationtissue damagecardiovascular riskbiological aging

Who is Dr. Diab right for?

Dr. Diab works best with high-performing adults who want to manage their health with the same rigor they apply to their careers. Executives, athletes, and driven professionals seeking biological age reversal or metabolic optimization are a strong fit. Patients dealing with hormonal imbalance, joint deterioration, or chronic inflammation benefit from his structured clinical tracks. He is especially effective with adults who want proactive, data-driven care rather than reactive treatment.

Similar Doctors Nearby

Frequently Asked Questions

Dr. Diab specializes in executive health, functional medicine, and preventive medicine. His clinical focus includes biological age reversal, longevity optimization, hormone calibration, peptide therapy, and stem cell signaling protocols. He also conducts comprehensive metabolic and genomic assessments through the Executive Asset Review.

Dr. Diab treats each patient as a biological asset requiring active management. He benchmarks clients against elite athlete and high-performance executive data rather than standard population ranges. His DiabOS platform pulls data from wearables, lab results, and DNA analysis into a live biomarker dashboard for ongoing guidance.

Dr. Diab organizes care into three tracks. BUILD addresses structural restoration using stem cell signaling therapy, exosome infusions, and joint repair protocols. PERFORMANCE targets metabolic output through peptide therapy and hormone calibration. RETURNS focuses on long-term preservation through telomere monitoring and inflammation control.

Yes. Dr. Diab conducts his stem cell protocols under IRB-2024-0847 and maintains GMP compliance standards. These protocols fall under the BUILD clinical track and focus on structural restoration and tissue repair.

Yes. Dr. Diab makes himself available to clients through secure messaging on the DiabOS platform. He provides real-time guidance on labs, protocols, and emerging clinical findings between scheduled visits.

The Executive Asset Review is a comprehensive single-session assessment. Dr. Diab delivers a Full Body MRI, genomics analysis, AI cardiac analysis, and a complete metabolic panel in one visit. It gives clients a detailed baseline across structural, cardiovascular, and metabolic health.

Yes. Hormone calibration and testosterone replacement therapy are core services at Diab Longevity. Dr. Diab uses these tools as part of the PERFORMANCE clinical track to optimize metabolic output and overall function.

Dr. Diab works primarily with high-performing adults, including executives and athletes. He focuses on patients who want proactive optimization rather than reactive care. His protocols target adults looking to reverse biological age, improve metabolic health, restore tissue function, or eliminate silent health risks before they compound.

Doctor profile last updated March 21, 2026